Carnegie

COMMISSIONED RESEARCH

RESULTS PREVIEW

18 February 2025 Sweden Technology Hardware & Equipment Research analysts: Örjan Rödén

Sensys Gatso Group

Share price: SEK62.7

Fair value range: SEK61.0-85.0

Preparing for the significant order from TRV – Q4(24) preview

Q4(24) expected on 28 February

We expect the Q4 report to reflect the ramping up of the organisation. Sensys Gatso Group (SGG) is taking on costs for the large order from Trafikverket (TRV, SEK850m in total order value) in Q4(24). We therefore expect EBIT of SEK30m to decline -11% Y/Y. As communicated by the company, TRV approved the FLUX solution, an important software component of the contract on 28 January 2025, which implies that the project can start the roll-out phase.

Adjusted estimates to reflect higher cost base

We revise our estimates to reflect somewhat delayed start-up of deliveries to TRV relative to our previous expectations, which impacts revenues. We also adjust the cost base as we expect SGG to increase its US cost base to compensate for the shortfall of revenues from the legislative process in lowa, which requires increased sales efforts in other states. Setting up an organisation in Saudi Arabia, which should offer significant growth potential, is also increasing the cost base. We now believe SGG will fall short of its SEK1bn revenue ambition for 2025. However, we expect SGG to reach the 15% EBITDA margin ambition for the same year.

Relative valuation model returns a fair value range of SEK61-85 per share

We use a relative valuation model to calculate our fair value range. We have selected Jenoptik, one of few listed peers with comparable P&L metrics, such as positive net profits, as the most relevant comparison. Jenoptik is currently valued at NTM EV/EBIT 11x, which we use as the relevant multiple. We apply this multiple to our 2027 EBIT forecast, adjust for net debt and discount to present value at a WACC of 12%. This forms the high end of our fair value range. For the low end, we have assumed a scenario of EBIT to be 25% lower than our forecast. Our forecasts imply substantial growth combined with margin expansion, which is a challenge to reach. Difficulties in getting the roll-out plan in Sweden on time or more setbacks in the US, where states could turn negative on speed enforcement, are examples of negative factors that could lead to a lower EBIT relative to our forecasts.

Upcoming events

Q4 Report: 28 Feb 2025Q1 Report: 24 Apr 2025

AGM 2025: 08 May 2025

• Q2 Report: 21 Aug 2025

Changes in this report										
	From	To	Chg							
EPS adj. 2024e	n.a.	1.57	n.a.							
EPS adj. 2025e	n.a.	4.4	n.a.							
EPS adj. 2026e	n.a.	7.3	n.a.							

Key facts	
No. shares (m)	11.5
Market cap. (USDm) 68
Market cap. (SEKm)	723
Net IB Debt. (SEKm) 156
Adjustments (SEKm) 0
EV (2024e) (SEKm)	879
Free float	81.7%
Avg. daily vol. ('000)	8
Risk	High Risk
Fiscal year end	December
Share price as of (C	ET) 17 Feb 2025 17:29

Key figures (SEK)	2023	2024e	2025e	2026e
Sales (m)	624	678	897	1,139
EBITDA (m)	85	82	138	176
EBIT (m)	39	38	86	124
EPS	1.06	1.57	4.42	7.29
EPS adj.	1.06	1.57	4.42	7.29
DPS	0.00	0.00	0.00	0.00
Sales growth Y/Y	26%	9%	32%	27%
EPS adj. growth Y/Y	-34%	48%	181%	65%
EBIT margin	6.3%	5.6%	9.6%	10.9%
P/E adj.	59.3	39.9	14.2	8.6
EV/EBIT	23.8	24.0	10.3	7.2
EV/EBITA	23.8	24.0	10.3	7.2
EV/EBITDA	11.0	11.1	6.4	5.1
P/BV	1.1	1.1	1.0	0.9
Dividend yield	0.0%	0.0%	0.0%	0.0%
FCF yield	-20.6%	-9.9%	-3.7%	-3.2%
Equity/Total Assets	66.0%	50.6%	51.3%	52.1%
ROCE	4.3%	4.2%	7.9%	10.6%
ROE adj.	1.9%	2.8%	7.5%	11.3%
Net IB debt/EBITDA	1.2	1.9	1.2	1.0



Source: Carnegie Research, FactSet, Millistream & company data

This report has been commissioned and sponsored by Sensys Gatso Group. Commissioned research is considered to be marketing communication (i.e. not investment research under MiFID II). This material may be subject to restrictions on distribution in certain areas. For more information, see disclosures and disclaimers at the end of this report



Equity story

Near term: 6-12m Sensys Gatso Group (SGG) has been awarded several significant orders recently, such as the 12-year contract with the Swedish Trafikverket worth SEK850m. We expect these orders to boost sales, in particular in the System Sales business line. Meanwhile, the Managed Services business has continued to report double-digit growth from mainly the US part of the business, with a steady flow of new contracts supporting future sales. The combined effect will accelerate growth and improve margins, according to our forecasts. SGG has also invested in its technical platform over the past few years, and we expect the company to see lower cost growth as the platform is deployed in its commercial offering.

Long term: 5Y+

Many areas are increasing investments in road safety. Lower traffic mortality and fewer injuries are a gain for society. Lower speed, another effect of safer roads, also improves air quality and reduces greenhouse emissions. With public finances increasingly challenged by an ageing population, there is growing demand for solutions that do not require large upfront investments. SGG is at the crossroads of these trends, offering high-end products that e.g. can identify drivers or drivers' use of mobile phones while being affordable for the client. Managed Services supplies a full-service solution without any need for the customer to invest in expensive equipment.

Key risks:

- · System sales are volatile and hard to forecast in the short term
- · Road traffic safety is highly regulated and therefore exposed to political risks
- SGG is pursuing a growth strategy and could therefore enter markets with higher geopolitical risks than western markets

Company description

The Sensys Gatso Group is a leading provider of automated traffic enforcement solutions with a strong global presence. The company's mission is saving lives by changing the driving behaviour of motorists. Its products aim to reduce vehicle speed and red-light negation by optimising traffic flows and by contributing to a sustainable urban environment, working in close partnership with governments and other authorities. The company was formed in 2015 from the merger of Gatso, founded in the Netherlands, and Sensys, founded in Sweden. Its main markets are Sweden, the US and the Netherlands.

Key industry drivers

- · Speed enforcement saves lives and healthcare costs
- · Lower speed contributes to a sustainable society
- · Limited public spending

Industry outlook

 We expect market growth to remain strong in particular in the Managed Services business area and in the US. Many emerging markets are prioritising road safety, which offers new growth opportunities

Largest shareholders

Gatso Special Products B.	17.7%
Per Wall	5.0%
Avanza Pension	4.4%

Cyclicality

Key peers

Cyclicality: No Not cyclical Jenoptik (listed), Vitronic, Verra, Idemia (all unlisted)


Valuation and methodology


We use a relative valuation model to calculate our fair value range. We have selected Jenoptik, one of few listed peers with comparable P&L metrics, as the most relevant comparison. The companies are different in nature, speed enforcement is just part of Jenoptik, which is also a large cap with market capitalisation of >SEK10bn. Jenoptik also has higher margins than SGG. This could qualify for a discount. On the other hand, SGG is growing faster, both in reported numbers and in our forecasts, which justifies a premium. Taken all together, we view the Jenoptik EV/EBIT multiple to be a good relative valuation metric. Jenoptik is currently valued at NTM EV/EBIT IIx, which we use as multiple in our calculation.

Fair value range 12m



The high end of our fair value range is based on SGG meeting our current earnings forecast for 2027, implying that the company will meet its 2025 ambition of an EBITDA margin of 15% and an EV/EBIT of 11x. The low end is based on 25% lower EBIT 2027e than we currently forecast and an EV/EBIT of 11x.








Source: Carnegie Research & company data




Sensys Gatso Group in key charts

Sales and sales growth Y/Y




Source: Company data, Carnegie Research

EBITDA and **EBITDA** margin



Source: Company data, Carnegie Research

Operating cash flow and free cash flow



Source: Company data, Carnegie Research



Estimate revisions

We revise our estimates to reflect somewhat delayed start-up of deliveries to TRV relative to our previous expectations, which is impacting revenues. We also adjust the cost base as we expect SGG to increase its US cost base to compensate for the shortfall of revenues from the legislative process in Iowa, which requires increased sales efforts in other states. Setting up an organisation in Saudi Arabia, which offer significant growth potential, is also increasing the cost base. We now believe SGG will fall short of its SEK1bn revenue ambition for 2025. However, we expect SGG to reach the 15% EBITDA margin ambition for the same year. We do not rule out that SGG can reach the SEK1bn ambition for revenues if all moving parts go in the right direction, although we view this probability to be low currently. Note that owing to a change in platform, EPS estimate changes show as n.a. in the table on the front page of this report.

	2024e	2024e		2025e	2025e		2026e	2026e	
SGG - Estimate changes	Old	New	Chg	Old	New	Chg	Old	New	Chg
Sales	678	678	0%	897	897	0%	1,139	1,139	0%
Growth	9%	9%	+0 bps	32%	32%	+0 bps	27%	27%	+0 bps
EBIT	38	38	0%	86	86	0%	124	124	0%
EBIT margin	5.6%	5.6%	+0 bps	9.6%	9.6%	+0 bps	10.9%	10.9%	+0 bps
EO	0	0	n.m	0	0	n.m	0	0	n.m
Adj EBIT	38	38	0%	86	86	0%	124	124	0%
Adj EBIT margin	5.6%	5.6%	+0 bps	9.6%	9.6%	+0 bps	10.9%	10.9%	+0 bps
Pre-tax profit	24	24	0%	66	66	0%	104	104	0%
Net profit	18	18	0%	51	51	0%	80	80	0%
EPS	1.6	1.6	0%	4.4	4.4	0%	7.0	7.0	0%
EPS adj	1.6	1.6	0%	4.4	4.4	0%	7.0	7.0	0%

Source: Carnegie Research, Company data



Valuation and risks


We have a fair value of SEK61-85 per share based on a relative NTM EV/EBIT multiple of Jenoptik.

Relative valuation model

We use a relative valuation model to calculate our fair value range. We have selected Jenoptik, one of few listed peers with comparable P&L metrics, such as positive net profits, as the most relevant comparison. The companies are different in nature; speed enforcement is just part of Jenoptik, which is also a large cap with market capitalization of SEK14.0bn. Jenoptik also has higher margins at 12–13% in 2022 and 2023, compared with SGG that has posted 6.2–6.3% in the same years. This could qualify for a discount. On the other hand, SGG is growing faster, both in reported numbers and in our forecasts, which justifies a premium. Taken all together, we view the Jenoptik EV/EBIT multiple to be a good relative valuation metric.

Jenoptik is currently valued at NTM EV/EBIT 11x, which we use as relevant multiple. This is below the average of 15x for the last 10 years, offering upside to our fair value range if there is a return to the mean in the chart below.

Jenoptik, EV/EBIT NTM



Source: FactSet, Carnegie Research

We apply this multiple to our 2027 EBIT forecast, adjust for net debt and discount to present value at a WACC of 12%. This forms the high end of our fair value range.

18 February 2025



Fair value calculation, high-end of range

EBIT, 2027e, SEKm	140
EV/EBIT multiple	П
Enterprise value, SEKm	1,535
Net debt 2025e, SEKm	163
Equity value, SEKm	1,372
WACC	12.0%
Present value, SEKm	977
Shares, m	11.5
Value per share, SEK	85.0

Source: Carnegie Research

For the low end, we have assumed a scenario of EBIT to be 25% lower than our forecast. Our forecasts imply substantial growth combined with margin expansion, which is a challenge to reach. Difficulties in getting the roll-out plan in Sweden on time or more setbacks in the US, where states could turn negative on speed enforcement, are examples of negative factors that could lead to a lower EBIT relative to our forecasts.

Fair value calculation, low-end of range

EBIT, 2027e -25%, SEKm	105
EV/EBIT multiple	11
Enterprise value, SEKm	1,151
Net debt 2025e, SEKm	163
Equity value, SEKm	988
WACC	12.0%
Present value, SEKm	703
Shares, m	11.5
Value per share, SEK	61.0

Source: Carnegie Research

Risks

- System sales are volatile and hard to forecast in the short term
- Road traffic safety is highly regulated and therefore exposed to political risks
- SGG is pursuing a growth strategy and could therefore enter markets with higher geopolitical risks than western markets.



Interim figures

	2023				2024				2025							
SEKm	Q١	Q2	Q3	Q4	Q١	Q2	Q3	Q4e	Qle	Q2e	Q3e	Q4e	2023	2024e	2025 e	2026e
Sales	113	133	157	221	125	167	141	245	134	214	230	318	624	678	897	1,139
Growth	0%	7%	65%	37%	10%	26%	-10%	11%	8%	28%	63%	30%	26%	9%	32%	27%
Adj EBIT	-9	5	8	34	-7	14	ı	30	-4	26	18	46	39	38	86	124
Adj EBIT margin	-7.6%	4.1%	5.3%	15.4%	-5.6%	8.1%	0.7%	12.4%	-3.0%	12.2%	7.8%	14.4%	6.3%	5.6%	9.6%	10.9%
EO	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EBIT	-9	5	8	34	-7	14	- 1	30	-4	26	18	46	39	38	86	124
EBIT margin	-7.6%	4.1%	5.3%	15.4%	-5.6%	8.1%	0.7%	12.4%	-3.0%	12.2%	7.8%	14.4%	6%	6%	10%	11%
Net financials	-7	ı	1	-11	0	-1	-8	-5	-5	-5	-5	-5	-16	-14	-20	-20
Pre-tax Profit	-16	7	9	23	-7	13	-7	25	-9	21	13	41	23	24	66	104
Tax	-4	2	-5	-3	2	-3	-1	-4	2	-5	-3	-9	-10	-6	-15	-24
Tax rate	-26%	-32%	52%	13%	29%	23%	-17%	16%	23%	23%	23%	23%	44%	26%	23%	23%
Net profit	-14	4	8	15	-6	10	-7	21	-7	16	10	32	12	18	51	80
EPS (SEK)	-1.2	0.3	0.7	1.3	-0.5	0.9	-0.6	1.8	-0.6	1.4	0.9	2.7	1.1	1.6	4.4	7.0
EPS Adj (SEK)	-1.2	0.3	0.7	1.3	-0.5	0.9	-0.6	1.8	-0.6	1.4	0.9	2.7	1.1	1.6	4.4	7.0
													Source: Co	mbanv dato	ı. Carnegie	Research



Financial statements

Profit & loss (SEKm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025 e	2026e
Sales	293	380	406	455	507	495	624	678	897	1,139
COGS	-177	-219	-261	-293	-301	-270	-371	-404	-534	-677
Gross profit	116	162	145	162	206	225	253	275	363	461
Other income & costs	-132	-124	-116	-102	-122	-152	-167	-193	-225	-285
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	0
EBITDA	-16	38	29	59	84	73	85	82	138	176
Depreciation PPE	-5	-11	-27	-22	-20	-32	-40	-40	-46	-46
Depreciation lease assets	0	0	0	0	0	0	0	0	0	0
Amortisation other intangibles	-34	-26	-26	-26	-18	-11	-6	-4	-6	-6
EBITA	-55	1	-24	- 11	46	31	39	38	86	124
EBIT	-55	ı	-24	- 11	46	31	39	38	86	124
Share in ass. operations and JV	0	0	0	0	0	0	-2	0	0	0
Net financial items	-10	-2	-3	-8	1	2	-15	-14	-20	-15
of which interest income/expenses	-5	-2	-4	-5	-5	-4	-7	-14	-20	-15
Pre-tax profit	-65	-1	-28	2	47	33	23	24	66	109
Taxes	3	-i	12	Ī	-12	-13	-10	-6	-15	-25
Post-tax minorities interest	4	i	2	i	-2	-1	-1	Ō	0	0
Discontinued operations	0	0	0	0	0	0	0	0	0	0
Net profit	-58	-2	-13	5	33	19	12	18	51	84
Adjusted EBITDA	-16	38	29	59	84	73	85	82	138	176
Adjusted EBITA	-55	1	-24	11	46	31	39	38	86	124
Adjusted EBIT	-55	1	-24	11	46	31	39	38	86	124
Adjusted net profit	-58	-2	-13	5	33	19	12	18	51	84
Sales growth Y/Y	-32.9%	29.8%	6.8%	12.0%	11.4%	-2.4%	26.1%	8.8%	32.2%	26.9%
EBITDA growth Y/Y	-52.7/6 -chg	+chg	-23.9%	108.1%	40.5%	-12.2%	16.3%	-3.9%	68.5%	27.5%
EBITA growth Y/Y	-chg	+chg	-chg	+chg	324.2%	-32.9%	27.5%	-3.3%	126.7%	44.1%
EBIT growth Y/Y	-chg	+chg	-chg	+chg	324.2%	-32.7%	27.5%	-3.3%	126.7%	44.1%
•	_	-	-	-						
EBITDA margin	-5.4%	9.9%	7.0%	13.1%	16.5%	14.8%	13.7%	12.1%	15.4%	15.5%
EBITA margin	nm	0.2%	nm	2.4%	9.1%	6.2%	6.3%	5.6%	9.6%	10.9%
EBIT margin	-18.7%	0.2%	-6.0%	2.4%	9.1%	6.2%	6.3%	5.6%	9.6%	10.9%
Tax rate	5.3%	-125.5%	45.1%	-59.7%	26.0%	39.4%	43.9%	25.6%	23.0%	23.0%
Cash flow (SEKm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
EBITDA	-16	38	29	59	84	73	85	82	138	176
Paid taxes	I	0	0	2	0	-12	-5	-15	-8	-13
Change in NWC	-26	15	-36	-42	-61	64	-103	-22	-32	-71
Non cash adjustments	I	-3	3	-4	-14	0	4	-18	-26	-21
Discontinued operations	0	0	0	0	0	0	0	0	0	0
Total operating activities	-39	49	-4	15	9	126	-18	27	73	72
Capex tangible assets	-9	-16	-41	-19	-24	-19	-83	-50	-55	-55
Capex - other intangible assets	-4	-5	-4	-14	-18	-26	-20	-35	-25	-25
Acquisitions/divestments	0	0	0	0	0	0	0	0	0	0
Total investing activities	-13	-21	-45	-33	-42	-45	-103	-85	-80	-80
Net financial items	-10	-2	-3	-8	1	2	-15	-14	-20	-15
Lease payments	0	0	-12	-12	-11	-11	-14	0	0	0
Dividend paid and received	0	0	0	0	0	0	0	0	0	0
Share issues & buybacks	87	0	0	71	0	0	0	0	0	0
Change in bank debt	-9	-10	36	14	19	-44	84	300	0	0
Total financing activities	78	-10	24	73	-4	-55	71	300	Ö	0
Operating cash flow	-39	49	-4	15	9	126	-18	27	73	72
Free cash flow	-63	26	-64	-37	-42	72	-149	-72	-27	-23
Net cash flow	26	17	-25	55	-36	25	-50	242	-7	-8
Change in net IB debt	36	28	-48	54	-44	82	-122	-58	-7	-8
Capex / Sales	2.9%	4.3%	10.2%	4.2%	4.8%	3.8%	13.2%	7.4%	6.1%	4.8%
NWC / Sales	19.0%	16.6%	15.6%	19.6%	27.7%	29.6%	27.3%	34.2%	28.8%	27.2%
		»			, -				ania Danagrah 0	

Source: Carnegie Research & company data



Financial statements, cont.

Balance sheet (SEKm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
Acquired intangible assets	239	251	257	242	251	277	273	273	273	273
Other fixed intangible assets	91	73	53	47	57	69	88	103	105	107
Tangible assets	35	42	101	86	92	105	128	158	190	222
Lease assets	0	0	0	0	0	0	0	0	0	0
Fixed assets	404	404	457	416	436	491	533	587	614	635
Inventories (2)	63	72	87	127	97	85	100	109	153	194
Receivables (2)	71	57	75	68	141	67	182	197	179	228
Other current assets	0	0	4	3	2	0	0	0	0	0
Cash & cash equivalents (I)	59	77 220	52	108	72	100	49	291	284	276
Current assets Total assets	221 624	228 632	249 706	35 I 767	361 797	337 828	430 964	705 1,292	760 1,373	879 1,514
Shareholders' equity	419	454	450	517	561	626	633	651	702	786
Minorities	1	0	-	-2	0	0	3	3	3	3
Total equity	420	454	449	515	562	626	636	654	704	788
Deferred tax	23	17	10	5	3	9	8	8	8	8
LT IB debt (I)	56 0	49 0	39 23	37 19	44 14	44 12	71	71	71 12	71
Lease libilities LT liabilities	87	72	23 77	66	65	7 5	12 103	12 103	103	12 103
ST IB debt (I)	26	10	57	53	50	9	64	364	364	364
Payables (2)	31	28	47	62	37	20	55	68	90	114
Accrued exp. & other NWC items (2)	60	67	74	70	76	98	106	104	112	145
Other ST non-IB liabilities	0	0	2	2	8	0	0	0	0	0
Current liabilities	117	106	180	187	170	127	225	535	566	622
Total equity and liabilities	624	632	706	767	797	828	964	1,292	1,373	1,514
• •				0	35		99			
Net IB debt (=1)	23 71	-18 56	67 71	107	35 173	-35 120	221	156 242	163 274	172 345
Net working capital (NWC) (=2)	487	492	532	588	637	661	756	1,065	1,123	1,220
Capital employed (CE) Capital invested (CI)	436	422	483	483	573	570	710	777	842	947
. , ,										
Equity / Total assets	67%	72%	64%	67%	70%	76%	66%	51%	51%	52%
Net IB debt / EBITDA	-1.5	-0.5	2.3	0.0	0.4	-0.5	1.2	1.9	1.2	1.0
Per share data (SEK)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
Adj. no. of shares in issue YE (m)	7.96	10.61	10.75	10.99	11.52	11.52	11.52	11.53	11.53	11.53
Diluted no. of Shares YE (m)	7.96	10.61	10.75	10.99	11.52	11.52	11.52	11.53	11.53	11.53
EPS	-7.17 -7.17	-0.21 -0.21	-1.25 -1.25	0.46 0.46	2.89 2.89	1.61 1.61	1.06	1.57 1.57	4.42 4.42	7.29 7.29
EPS adj. CEPS	-2.36	3.78	2.61	3.87	5.25	4.33	1.06 4.02	5.39	8.93	11.8
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
BVPS	52.6	42.8	41.8	47.0	48.7	54.3	54.9	56.5	60.9	68.2
Performance measures	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
ROE	-14.5%	-0.4%	-3.0%	1.0%	6.0%	3.1%	1.9%	2.8%	7.5%	11.3%
Adj. ROCE pre-tax	-12.7%	0.3%	-4.5%	1.3%	8.5%	5.8%	4.3%	4.2%	7.9%	10.6%
Adj. ROIC after-tax	-11.9%	0.3%	-3.0%	3.6%	6.4%	3.3%	3.4%	3.8%	8.2%	10.7%
Valuation	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
FCF yield	-8.7%	3.6%	-8.8%	-5.2%	-5.9%	9.9%	-20.6%	-9.9%	-3.7%	-3.2%
Dividend yield YE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Dividend payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Dividend + buy backs yield YE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EV/Sales YE	3.41	4.02	3.04	3.24	1.81	1.79	1.50	1.34	0.99	0.79
EV/EBITDA YE	neg.	40.7	43.2	24.8	11.0	12.1	11.0	11.1	6.4	5.1
EV/EBITA YE	neg.	>50	neg.	>50	20.0	28.7	23.8	24.0	10.3	7.2
EV/EBITA adj. YE	neg.	>50	neg.	>50	20.0	28.7	23.8	24.0	10.3	7.2
EV/EBIT YE	neg.	>50	neg.	>50	20.0	28.7	23.8	24.0	10.3	7.2
P/E YE	nm	nm	nm	>50	26.4	49.5	>50	41.7	14.2	8.6
P/E adj. YE	nm	nm	nm	>50	26.4	49.5	>50	41.7	14.2	8.6
P/BV YE	2.33	3.41	2.60	2.85	1.57	1.47	1.32	1.16	1.03	0.92
Share price YE (SEK)	122	146	109	134	76.5	79.8	72.6	65.5	62.7	

Source: Carnegie Research & company data



Disclosures and disclaimers

Carnegie Investment Bank AB

Carnegie Investment Bank AB (publ.) is a leading investment bank with a Nordic focus. The Carnegie group of companies, together "Carnegie", generates added value for institutions, companies and private clients in the areas of trade in securities, investment banking and private banking. Carnegie has approximately 600 employees, located in offices in six countries

Valuation, methodology, and assumptions

Commissioned research reports include the analyst's assessment of a fair value range over the coming six to 12 months based on various fundamental valuation methods. A commonly used method is DCF valuation, where future cash flows are discounted to today. Analysts may also use different valuation multiples, e.g. P/E ratio and EV/EBIT multiples, relative to industry peers. For companies where it is appropriate, a fair value range can also be based on the analyst's assessment of a fair ratio relative to the net asset value of the company. Fair value ranges represent the assessment of the analyst(s) at the time of writing

Frequency of update

Carnegie's research analysis consists of case-based analyses, which implies that the frequency of the analytical report may vary over time. Unless otherwise expressly stated in the report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.

Analyst certification

The research analyst or analysts responsible for the content of this commissioned research report certify that, notwithstanding the existence of any potential conflicts of interests referred to herein, the views expressed in this commissioned research report accurately reflect the research analyst's personal views about the companies and securities covered. It is further certified that the research analyst has not been, nor is or will be, receiving direct or indirect compensation related to the specific ratings or views contained in this commissioned research report.

Potential conflicts of interest

Carnegie, or its subsidiaries, may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in this report. Any such publicly announced business activity, during the past 12 months, will be referred to in this commissioned research report. A set of rules handling conflicts of interest is implemented in the Carnegie Group. Investment Banking and other business departments in Carnegie are surrounded by information barriers to restrict the flows of sensitive information. Persons outside such barriers may gain access to sensitive information only after having observed applicable procedures. The remuneration of persons involved in preparing this commissioned research report is not tied to investment banking transactions performed by Carnegie or a legal person within the same group.

Confidential and non-public information regarding Carnegie and its clients, business activities and other circumstances that could affect the market value of a security ("sensitive information") is kept strictly confidential and may never be used in an undue manner.

Internal guidelines are implemented in order to ensure the integrity and independence of research analysts. In accordance with the guidelines the research department is separated from the Investment Banking department and there are no reporting lines between the research department and Investment Banking. The guidelines also include rules regarding, but not limited to, the following issues; contacts with covered companies, prohibition against offering favourable recommendations, personal involvement in covered companies, participation in investment banking activities, supervision and review of research reports, analyst reporting lines and analyst remuneration.

Other material conflicts of interest

This report was commissioned and sponsored by the issuer (issuer-paid research).

Distribution restrictions

This commissioned research report is intended only for distribution to professional investors. Such investors are expected to make their own investment decisions without undue reliance on this commissioned research report. This commissioned research report does not have regard to the specific investment objectives, financial situation or particular needs of any specific person who may receive it. Investors should seek financial advice regarding the appropriateness of investing in any securities discussed in this commissioned research report and should understand that statements regarding future prospects may not be realized. Past performance is not necessarily a guide to future performance. Carnegie and its subsidiaries accept no liability whatsoever for any direct or consequential loss, including, without limitation, any loss of profits arising from the use of this commissioned research report or its contents. This commissioned research report may not be reproduced, distributed or published by any recipient for any purpose. The document may not be distributed to persons that are citizens of or domiciled in any country in which such distribution is prohibited according to applicable laws or other regulations.

This commissioned research report is distributed in Sweden by Carnegie Investment Bank AB. Carnegie Investment Bank AB is a bank incorporated in Sweden with limited liability which is authorised and regulated by the Swedish Financial Supervisory Authority (Finansinspektionen). In Finland this commissioned research report is issued by Carnegie Investment Bank AB, Finland Branch. The Finland branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Finnish Financial Supervisory Authority (Finansisia) to Norway this commissioned research report is issued by Carnegie AS, a wholly-owned subsidiary of Carnegie Investment Bank AB. Carnegie AS is regulated by the Financial Supervisory Authority of Norway (Finansitsynet). In Denmark this commissioned research report is issued by Carnegie Investment Bank AB, Denmark Branch. The Denmark branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Danish Financial Supervisory Authority (Finanstilsynet).

subject to limited regulation by the Danish Financial Supervisory Authority (Finanstilsynet). This commissioned research report is distributed in the US by Carnegie, Inc., a US-registered broker-dealer and a member of FINRA and SIPC. Carnegie's research analysts located outside of the US are employed by non-US affiliates of Carnegie Inc. ("non-US affiliates") that are not subject to FINRA regulations. Generally, Carnegie research analysts are not registered with or qualified as research analysts with FINRA, and therefore are not subject to FINRA rule 2241 restrictions intended to prevent conflicts of interest by, among other things, prohibiting certain compensation practices, restricting trading by analysts and restricting communications with the companies that are the subject of the research report. Research reports distributed in the U.S. are intended solely for major US institutional investors and US institutional investors as defined under Rule ISa-6 of the Securities Exchange Act of I934. This commissioned research report is provided for informational purposes only and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of any offer to buy any securities. Reports regarding equity products are prepared by non-US affiliates of and distributed in the United States by Carnegie Inc. under Rule ISa-6(a)(3). When distributed by Carnegie Inc, Carnegie Inc. takes responsibility for the commissioned research report. Any US person who wishes to effect ansactions based on this commissioned research report should contact Carnegie Inc. Investors in the US should be aware that investing in non-US securities entails certain risks. The securities of non-US issuers may not be registered with, or be subject to, the current information reporting and audit standards of the US Securities and Exchange Commission. This commissioned research report has been issued in the UK by Carnegie UK which is the UK Branch of Carnegie Investment Bank AB. Carnegie UK is authorised and regulated by the F

Research Disclaimer

This commissioned research report is provided solely for information. It does not constitute or form part of, and shall under no circumstances be considered as an offer to sell or a solicitation of an offer to purchase or sell any relevant financial instrument.

This commissioned research report has been requested and paid for by the issuer and should therefore be considered a marketing communication (i.e. not investment research). Payment for the report has been agreed in advance on a non-recourse basis. As commissioned research, this material can be considered an acceptable minor non-monetary benefit under MiFID II. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. However, it is still subject to a prohibition on dealing ahead of the dissemination of the report.

Carnegie Investment Bank AB is responsible for the preparation of this commissioned research report in Sweden, Finland, Denmark, and the UK. Carnegie AS is responsible for the preparation of this commissioned research report in Norway. Carnegie Inc. is responsible for this research report in the IIS

The information in this commissioned research report was obtained from various sources. While all reasonable care has been taken to ensure that the information is true and not misleading. Carnegie gives no representation or warranty, express or implied, about its accuracy or completeness. Carnegie, its subsidiaries and any of their officers or directors may have a position, or otherwise be interested in, transactions in securities that are directly or indirectly the subject of this commissioned research report. Any significant financial interests held by the analyst, Carnegie or a legal person in the same group in relation to the issuer will be referred to in the company-specific disclosures.

Company specific disclosures

The following disclosures relate to relationships between Carnegie Investment Bank AB (with its subsidiaries, "Carnegie") and the issuer or an affiliate.

Parts of this commissioned research report may have been submitted to the issuer prior to its publication.

Copyright © 2025 Carnegie



Commissioned Research sponsored by Sensys Gatso Group

18 February 2025

Carnegie Investment Bank AB

Regeringsgatan 56 SE-103 38 Stockholm

Tel +46 8 5886 88 00 Fax +46 8 5886 88 95 www.carnegie.se

A member of the Stockholm Stock Exchange

Carnegie AS

Fjordalleen 16, 5th Floor PO Box 684, Sentrum NO-0106 Oslo Tel +47 22 00 93 00 Fax +47 22 00 94 00 www.carnegie.no A member of the Oslo Stock Exchange Carnegie Investment Bank, Denmark Branch

Overgaden neden Vandet 9B PO Box 1935 DK-1414 Copenhagen K

Tel +45 32 88 02 00 Fax +45 32 96 10 22 www.carnegie.dk

A member of the Copenhagen Stock Exchange

Carnegie, Inc.

20 West 55th St. ,
New York N.Y. 10019
Tel +1 212 262 5800 Fax +1 212 265 3946
www.carnegiegroup.com
Member FINRA / SIPC

Carnegie Investment Bank AB, Finland Branch

Eteläesplanadi 2 PO Box 36 FI-00131 Helsinki

Tel +358 9 618 71 230 Fax +358 9 618 71 720 www.carnegie.fi

A member of the Helsinki Stock Exchange

Carnegie Investment Bank AB, UK Branch

Finwell House, 26 Finsbury Square London EC2A IDS

Tel +44 20 7216 4000 Fax +44 20 7417 9426 www.carnegie.co.uk

Regulated by the FCA in the conduct of Designated Investment Business in the UK